Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.64 |
| ▸ | RAB9A | P51151 | 7/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | FAAH | O00519 | 3/20 | 0.61 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11717444 | 0.81 | NPC1 (0.76) | NPC1RAB9AKMT2AFAAHKLF5 | |
| SCHEMBL107323 | 0.81 | RAB9A (0.81) | NPC1RAB9AKMT2AKLF5NAMPT | |
| SCHEMBL5039674 | 0.81 | NPC1 (0.68) | NPC1RAB9AKMT2AFAAHKLF5 | |
| SCHEMBL5039677 | 0.81 | NPC1 (0.68) | NPC1RAB9AKMT2AFAAHKLF5 | |
| SCHEMBL3223389 | 0.80 | RAB9A (0.65) | NPC1RAB9AKMT2AFAAHMEN1 | |
| SCHEMBL17822164 | 0.79 | NPC1 (1.00) | NPC1RAB9AKMT2AKLF5MEN1 | |
| SCHEMBL30666147 | 0.79 | NPC1 (1.00) | NPC1RAB9AKMT2AKLF5MEN1 | |
| SCHEMBL13423693 | 0.79 | HIF1A (0.60) | NPC1RAB9AKMT2ANAMPTMEN1 | |
| SCHEMBL5045742 | 0.79 | NPC1 (0.65) | NPC1RAB9AKMT2AFAAHKLF5 | |
| SCHEMBL10248246 | 0.78 | FAAH (0.66) | NPC1RAB9AKMT2AFAAHKLF5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | NPC1 2916/4885RAB9A 3552/4885KMT2A 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.